A comprehensive map of molecular drug targets R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, ... Nature reviews Drug discovery 16 (1), 19-34, 2017 | 2117 | 2017 |
Virtual and biomolecular screening converge on a selective agonist for GPR30 CG Bologa, CM Revankar, SM Young, BS Edwards, JB Arterburn, ... Nature chemical biology 2 (4), 207-212, 2006 | 932 | 2006 |
In vivo effects of a GPR30 antagonist MK Dennis, R Burai, C Ramesh, WK Petrie, SN Alcon, TK Nayak, ... Nature chemical biology 5 (6), 421-427, 2009 | 606 | 2009 |
Unexplored therapeutic opportunities in the human genome TI Oprea, CG Bologa, S Brunak, A Campbell, GN Gan, A Gaulton, ... Nature reviews Drug discovery 17 (5), 317-332, 2018 | 374 | 2018 |
Drug repurposing from an academic perspective TI Oprea, JE Bauman, CG Bologa, T Buranda, A Chigaev, BS Edwards, ... Drug Discovery Today: Therapeutic Strategies 8 (3-4), 61-69, 2011 | 363 | 2011 |
Identification of a GPER/GPR30 Antagonist with Improved Estrogen Receptor Counterselectivity MK Dennis, AS Field, R Burai, C Ramesh, WK Petrie, CG Bologa, ... The Journal of Steroid Biochemistry and Molecular Biology, 2011 | 332 | 2011 |
How many rare diseases are there? M Haendel, N Vasilevsky, D Unni, C Bologa, N Harris, H Rehm, ... Nature reviews drug discovery 19 (2), 77-78, 2020 | 329 | 2020 |
DrugCentral: online drug compendium O Ursu, J Holmes, J Knockel, CG Bologa, JJ Yang, SL Mathias, SJ Nelson, ... Nucleic acids research, gkw993, 2016 | 285 | 2016 |
Pharos: collating protein information to shed light on the druggable genome DT Nguyen, S Mathias, C Bologa, S Brunak, N Fernandez, A Gaulton, ... Nucleic acids research 45 (D1), D995-D1002, 2017 | 258 | 2017 |
Virtual screening in drug discovery J Alvarez, B Shoichet CRC press, 2005 | 193 | 2005 |
Modulation of bitter taste perception by a small molecule hTAS2R antagonist JP Slack, A Brockhoff, C Batram, S Menzel, C Sonnabend, S Born, ... Current Biology 20 (12), 1104-1109, 2010 | 178 | 2010 |
Microbial efflux pump inhibition: tactics and strategies G P Tegos, M Haynes, J Jacob Strouse, M Md T Khan, C G Bologa, ... Current pharmaceutical design 17 (13), 1291-1302, 2011 | 172 | 2011 |
Probe reports from the nih molecular libraries program Z Surviladze, A Waller, JJ Strouse, C Bologa, O Ursu, V Salas, ... Bethesda (MD), 2010 | 165 | 2010 |
DrugCentral 2021 supports drug discovery and repositioning S Avram, CG Bologa, J Holmes, G Bocci, TB Wilson, DT Nguyen, ... Nucleic acids research 49 (D1), D1160-D1169, 2021 | 159 | 2021 |
A Potent and Selective Inhibitor of Cdc42 GTPase Z Surviladze, A Waller, JJ Strouse, C Bologa, O Ursu, V Salas, ... | 150 | 2010 |
A crowdsourcing evaluation of the NIH chemical probes TI Oprea, CG Bologa, S Boyer, RF Curpan, RC Glen, AL Hopkins, ... Nature chemical biology 5 (7), 441-447, 2009 | 140 | 2009 |
DrugCentral 2018: an update O Ursu, J Holmes, CG Bologa, JJ Yang, SL Mathias, V Stathias, ... Nucleic acids research 47 (D1), D963-D970, 2019 | 133 | 2019 |
Lead-like, drug-like or “Pub-like”: how different are they? TI Oprea, TK Allu, DC Fara, RF Rad, L Ostopovici, CG Bologa Journal of Computer-Aided Molecular Design 21, 113-119, 2007 | 130 | 2007 |
Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists BS Edwards, C Bologa, SM Young, KV Balakin, ER Prossnitz, ... Molecular pharmacology 68 (5), 1301-1310, 2005 | 127 | 2005 |
TCRD and Pharos 2021: mining the human proteome for disease biology TK Sheils, SL Mathias, KJ Kelleher, VB Siramshetty, DT Nguyen, ... Nucleic Acids Research 49 (D1), D1334-D1346, 2021 | 125 | 2021 |